Vertex’s Upgraded IgA Nephropathy Outlook Might Change The Case For Investing In Vertex (VRTX)

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...
FierceBiotech

Vertex to tackle liver disease with Verve, putting up $60M to partner on gene editing program

Vertex Pharmaceuticals is getting deeper into in vivo gene editing. Months after partnering with Mammoth Biosciences, the storied biotech is back with another deal, ponying up $60 million to work with ...
Yahoo Finance

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas Medicine, Inc. EDIT announced entering into a licensing agreement with Vertex Pharmaceuticals VRTX for the development of the latter’s new sickle cell disease (SCD) gene therapy, Casgevy. Per ...
FierceBiotech

Vertex strikes deal with Merck KGaA to grow CRISPR/Cas9 toolkit

Vertex has regained limited rights to two DNA-dependent protein kinase (DNA-PK) inhibitors from Merck KGaA. Merck licensed the drugs and other assets for $230 million upfront two years ago but has now ...
Nasdaq

Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics

Vertex Pharmaceuticals (NASDAQ: VRTX) and its partner, CRISPR Therapeutics (NASDAQ: CRSP), have achieved significant progress with their drug targeting rare blood diseases beta thalassemia and sickle ...
Investopedia

Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...